The top five late-phase CROs in Europe
The strongest shortlist combines relevant trial experience with the services your study needs. This comparison counts each CRO once per trial, followed by a closer look at its three most frequent services.
Distinct trials
IQVIA
IQVIA combines clinical development services with a broad range of supporting functions. Its 408-trial footprint leads this comparison, with monitoring the largest service category, followed by laboratory and regulatory work.
Distinct trials
ICON
ICON provides outsourced clinical development services across the trial lifecycle. Its involvement in 295 trials combines substantial monitoring and laboratory experience, with 122 trials in each category.
Distinct trials
PPD
PPD is the clinical research business of Thermo Fisher Scientific. Laboratory services account for its largest service category across 289 trials, while 90 monitoring trials and 81 project-management trials add context to its clinical-operations experience.
Distinct trials
Parexel
Parexel provides clinical development and regulatory services. Regulatory work is its strongest category in this analysis, spanning 97 of its 195 trials, followed by clinical monitoring and project management.
Distinct trials
Syneos Health
Syneos Health offers full-service clinical development and functional-service arrangements. Monitoring is the clearest feature of its 149-trial footprint, covering 85 trials, followed by regulatory work and project management.
Distinct trials
Late-stage CROs and specialist providers by service
A service-specific comparison can produce a different shortlist. For each category below, we counted only trials where that provider was named for that service, including specialist laboratories and technology providers alongside CROs.
Laboratory providers for European late-phase trials
Laboratory experience creates a different shortlist from the overall CRO comparison. We compared laboratory providers across 898 European late-phase trials, including CRO laboratory businesses and specialist providers.
Distinct trials
Late-phase CROs for clinical monitoring
Monitoring experience is a useful lens for assessing a CRO’s involvement in clinical operations. We compared providers across 752 European late-phase trials with on-site, clinical or global monitoring services.
Distinct trials
Interactive response technology (IRT) for late-stage trials
Technology providers play a prominent role in interactive response services. This comparison covers IRT, IVRS and IWRS involvement across 703 European late-phase trials.
Distinct trials
Regulatory services for European Phase III and IV trials
Regulatory experience helps distinguish providers beyond their overall trial footprint. We compared regulatory expertise and application services across 627 European late-phase trials.
Distinct trials
Electronic data capture (EDC) for late-stage trials
For sponsors choosing a late-stage CRO, electronic data capture (EDC) is a separate provider decision; technology specialists lead this comparison. We compared EDC involvement across 608 European late-phase trials to identify the providers with the most trial experience in this service.
Distinct trials
CROs and data management providers for late-phase trials
Data management brings CROs and technology specialists into the same comparison. Across 572 European late-phase trials, we examined data-management and SDTM-programming involvement to see where experience is concentrated.
Distinct trials
Late-stage CROs for project management
Project-management experience offers a more focused view of a CRO’s operational involvement. We compared providers across 540 European late-phase trials with this service.
Distinct trials
Safety reporting and pharmacovigilance in late-phase trials
Safety reporting and pharmacovigilance produce a slightly different shortlist from the overall comparison. We examined provider involvement across 537 European late-phase trials with these services.
Distinct trials
Investigator recruitment for European late-stage trials
Investigator recruitment highlights the providers involved in building a trial’s investigator network. This comparison covers 479 European late-phase trials and concerns investigator recruitment, rather than patient enrollment.
Distinct trials
Statistical analysis and biostatistics for Phase III and IV trials
Statistical experience can help refine a shortlist for biostatistics support. We compared statistical-analysis and biostatistics involvement across 354 European late-phase trials.
Distinct trials
Medicinal product management for late-phase trials
Medicinal product management brings specialist providers to the front of the comparison. Across 325 European late-phase trials, we identified the organizations with the most experience in this service.
Distinct trials
Clinical outcome assessments for late-stage trials
Clinical outcome assessments draw on both specialist providers and CROs. We compared involvement in these assessments and electronic patient-reported outcome services across 315 European late-phase trials.
Distinct trials
CRO medical expertise for late-phase trials
Medical expertise and medical monitoring offer another way to compare CRO experience. This analysis covers 287 European late-phase trials and treats these services separately from clinical monitoring.
Distinct trials
Late-phase CROs and providers for medical writing
Medical-writing experience adds another dimension to a CRO shortlist. We compared provider involvement across 277 European late-phase trials with this service.
Distinct trials
Cardiac services for European Phase III and IV trials
Specialist providers feature prominently in cardiac services. We compared cardiac, ECG and EKG involvement across 175 European late-phase trials.
Distinct trials
Quality assurance and auditing for late-stage trials
Quality-assurance and auditing experience creates its own provider ordering. We compared involvement in these services across 133 European late-phase trials.
Distinct trials
Payment services for European late-phase trials
Payment services bring financial-technology specialists into the comparison. We examined payment and investigator-grant involvement across 101 European late-phase trials.
Distinct trials
Trial master file management for late-stage trials
Trial master file management highlights a different mix of service providers. We compared TMF and eTMF involvement across 51 European late-phase trials.
Distinct trials
Electronic consent (eConsent) in late-phase trials
Electronic consent produces a smaller comparison, covering 13 European late-phase trials. Within that group, we identified the providers with the most eConsent and electronic informed-consent experience.
Distinct trials
Study start-up for European Phase III and IV trials
The study-start-up comparison covers 11 European late-phase trials. It brings together start-up and the specified start-up/contract-negotiation roles in the directory’s service categories.
Distinct trials
A note on the data
Source: the TrialAgents public directory, using its 9 October 2026 snapshot, existing service categories and company identities, including legacy names. Only 1,986 of the source’s 5,950 trials have structured phase tags; the 3,964 untagged trials are excluded, so the rankings describe this dataset rather than the entire European market. Counts represent trial appearances, not proof of end-to-end trial delivery, quality or current capacity; services can overlap, and ties are ordered alphabetically.